AU Patent

AU2015227503B2 — Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

Assigned to Boehringer Ingelheim International GmbH · Expires 2017-02-23 · 9y expired

What this patent protects

CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE The present invention relates to a suspension formulation containing the active substance 3-Z-[1 (4-(N-(( 4-methylpiperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 -phen…

USPTO Abstract

CAPSULE PHARMACEUTICAL DOSAGE FORM COMPRISING A SUSPENSION FORMULATION OF AN INDOLINONE DERIVATIVE The present invention relates to a suspension formulation containing the active substance 3-Z-[1 (4-(N-(( 4-methylpiperazin- 1 -yl)-methylcarbonyl)-N-methyl-amino)-anilino)- 1 -phenyl methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015227503B2
Jurisdiction
AU
Classification
—
Expires
2017-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.